Met IR

DRUG2 trials

Sponsors

Elcelyx Therapeutics, Inc.

Conditions

Healthy SubjectsType 2 Diabetes Mellitus

Phase 1

Assessing the PK of Met DR, Met IR, and Met XR in Healthy Subjects

CompletedNCT02291510

Elcelyx Therapeutics, Inc.Healthy Subjects

Start: 2012-10-31End: 2012-12-31Updated: 2016-12-02

Phase 2

Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM

CompletedNCT02526524

Elcelyx Therapeutics, Inc.Type 2 Diabetes Mellitus

Start: 2015-09-30End: 2016-09-30Updated: 2018-04-27

Related Papers

Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes

PLoS ONE2018-09-2534 citations